Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors

NCT03988114 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03988114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03988114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Withdrawn
Start date
September 16, 2019
Completion date
March 23, 2023
Enrollment
0 (actual)
Sites
119

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer